Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer

Abstract

In the large majority of patients, triptorelin SR formulations suppressed serum testosterone concentrations to even <20 ng/dl. Testosterone should be routinely monitored in PC patients on ADT although further studies on the clinical benefit of very low testosterone levels and the target concentrations are still warranted.